Top-News
Biotechnologie USA

Alimera Sciences News

Aktie
WKN:  A2PVHE ISIN:  US0162592028 US-Symbol:  ALIM
4,01 €
+0,705 €
+21,33%
25.03.24 14:44:14
Handeln Depot/Watchlist
Aktienanzahl *
52,42 Mio.
Marktkapitalisierung *
173,01 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 06.03.2024

Alimera Sciences News

27.01.20 - PR Newswire
Alimera Sciences, Inc 13D/A filing
Alimera Sciences, Inc 13D/A filing PR Newswire
11.12.19 - PR Newswire
Almira Sciences, Inc 13D filing
Almira Sciences, Inc 13D filing PR Newswire
23.04.19 - ACCESSWIRE
Alimera Sciences to Report First Quarter Financial Results on Monday, April 29, 2019 and Provide Corporate Update
Conference Call to be held Tuesday April 30, 2019 at 9:00am Eastern Time
23.04.19 - ACCESSWIRE
Alimera Sciences Announces Multiple Posters and a Podium Presentation of Clinical Data for ILUVIEN(R) to be Presented at the Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting
ATLANTA, GA / ACCESSWIRE / April 23, 2019 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic ...
04.04.19 - ACCESSWIRE
Alimera Sciences Announces Expansion of Leadership Team with Appointment of Samer Kaba, MD as Chief Medical Officer
ATLANTA, GA / ACCESSWIRE / April 4, 2019 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic ...
25.03.19 - ACCESSWIRE
Alimera Sciences Announces Approval Received in the Mutual Recognition Procedure for New Indication for ILUVIEN(R) in Europe
- Indication for treatment of non-​infectious posterior uveitis further supports the uniqueness of ILUVIEN to consistently and continuously deliver treatment to reduce the recurrence of ...
21.03.19 - ACCESSWIRE
Alimera Sciences Announces Approval for ILUVIEN (R) in Kuwait
Kuwait Added to the Growing Number of Countries with Approval for ILUVIEN in the Middle East
06.03.19 - ACCESSWIRE
Alimera Sciences Announces the Reimbursement of ILUVIEN(R) in France
France is a Significant Market for Intravitreal Steroid Use
18.02.19 - ACCESSWIRE
Alimera Sciences Reports Record Fourth Quarter and 2018 Results
Fourth Quarter 2018 Highlights
05.02.19 - ACCESSWIRE
Alimera Sciences Announces Approval for ILUVIEN(R) in Lebanon
Lebanon will be the second Middle Eastern country to approve ILUVIEN
04.02.19 - ACCESSWIRE
Alimera Sciences to Report Fourth Quarter and Full Year 2018 Results on February 18, 2019
ATLANTA, GA / ACCESSWIRE / February 4, 2019 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic ...
07.01.19 - ACCESSWIRE
Alimera Sciences Affirms Record 2018 Revenues
Anticipates 2018 GAAP Net Revenue in Excess of $45 Million
17.12.18 - ACCESSWIRE
Alimera Sciences Announces Pricing Approval For ILUVIEN(R) in the U.A.E.
The U.A.E. becomes the first country in the Middle East to obtain pricing approval
29.11.18 - ACCESSWIRE
Alimera Sciences Appoints Rick Eiswirth as Chief Executive Officer
Co-​founder Dan Myers Named Non–Executive Chairman
26.11.18 - ACCESSWIRE
Alimera Sciences Announces Canadian Regulatory Approval for ILUVIEN(R)
ATLANTA, GA / ACCESSWIRE / November 26, 2018 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ...
09.11.18 - ACCESSWIRE
Alimera Sciences to Present at Upcoming Investor Conferences
ATLANTA, GA / ACCESSWIRE / November 9, 2018 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic ...
05.11.18 - ACCESSWIRE
Alimera Sciences Reports Third Quarter 2018 Results
Record Net Revenue of $11.1 Million in Q3 2018; U.S. Net Revenue up 20% Record U.S. End User Demand in Q3 2018 Net Loss and Adjusted EBITDA Loss Continue to Improve ...
23.10.18 - ACCESSWIRE
Alimera Sciences to Report Third Quarter 2018 Results November 5, 2018
ATLANTA, GA / ACCESSWIRE / October 23, 2018 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic ...
22.10.18 - ACCESSWIRE
Alimera Sciences Announces Six ILUVIEN(R) Posters to be Presented at 2018 American Academy of Ophthalmology
ATLANTA, GA / ACCESSWIRE / October 22, 2018 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic ...
17.09.18 - PR Newswire
Alimera Sciences Announces Nine Clinical Presentations and a Sponsored Symposium at 18th EURETINA Congress
Alimera Sciences Announces Nine Clinical Presentations and a Sponsored Symposium at 18th EURETINA Congress "CONTINUOUS MICRODOSING with ILUVIEN: Optimizing the ...

Newssuche

Videos

newspaper
07.05.24 +6,80%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: NG8K9X Hebel: 26 Laufzeit: OpenEnd Einstieg: Market ... Mehr »